Table 2.
Atherogenic profile of study subjects
| Normal Triglycerides n = 73 |
CHTG n = 85 |
FHTG n = 84 |
P value all |
P value* FHTG vs CHTG |
|
|---|---|---|---|---|---|
| Age (years) | 49 [45–54] | 50 [37–55] | 43 [37–47] b | 0.002 | 0.001 |
| BMI (kg/m2) | 26.4 [24.2–28.7] a | 28.7 [25.9–31.1] | 28.9 [26.1–32.1] | 0.008 | 0.813 |
| Waist (cm) | 90 [84–98] a | 94 [88–104] | 96 [88–100] | 0.004 | 0.800 |
| Leptin (μg/L) | 5.6 [2.3–13.6] | 8.7 [7.2–28] | 5.7 [2.6–8.7] | < 0.001 | < 0.001 |
| Adiponectin (μg/L) | 11.4 [8.8–14.6] a | 6.8 [4.3–10.4] | 5.9 [4.5–8.4] | < 0.001 | 0.146 |
| Apo B (mg/dL) | 103 [86–114] | 110 [109–117] | 91.8 [82–97.6] | < 0.001 | < 0.001 |
| Apo A-II (mg/dL) | 1894 [996–2858] | 426.5 [401.4–456.5] | 702 [497–1062] | < 0.001 | < 0.001 |
| Apo C-III (mg/dL) | 10.7 [7.3–13.4] | 30.68 [24.5–38] | 22.8 [13.6–37] | < 0.001 | 0.231 |
| ANGPTL3 (ng/mL) | 9 [6.6–11.2] | 18.8 [13.6–22] | 108 [10.8–372] | < 0.001 | < 0.001 |
| ANGPTL4 (ng/mL) | 50.5 [21.5–145.9] | 180.9 [151.9–225.3] | 384 [239–483] | < 0.001 | < 0.001 |
| FGF-19 (pg/mL) | 15 [10–81] | 15 [7–18] | 77 [10–156] b | 0.052 | 0.071 |
| FGF-21 (pg/mL) | 55.5 [32–89] | 12.5 [2–22] | 168 [66–316] | < 0.001 | < 0.001 |
| FGF-23 (pg/mL) | 25 [18–38] | 17.5 [16–22] | 33[22–50] | 0.127 | 0.417 |
| FABP1 (ng/mL) | 37 [2.15–302.1] a | 15.5 [13.6–20.8] | 13 [1–45] | 0.010 | 0.056 |
Median [25th percentile-75th percentile] or percentages are shown
Kruskall Wallis test for metabolic traits adjusted for age, BMI, triglycerides levels and sex;
a post hoc P < 0.01 by Dunn test: Normal triglycerides subjects different among the other groups
b post hoc P < 0.01 by Dunn test: FHTG subjects different only from CHTG subjects
c post hoc P < 0.01 by Dunn test: CHTG subjects different among the other groups
*U Mann-Whitney test